These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 20539909)

  • 1. New oral anticoagulant drugs in cardiovascular disease.
    Ahrens I; Lip GY; Peter K
    Thromb Haemost; 2010 Jul; 104(1):49-60. PubMed ID: 20539909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].
    Samama M; Conard J; Horellou MH; Le Flem L; Guinet C; Depasse F
    Ann Pharm Fr; 2010 Nov; 68(6):359-69. PubMed ID: 21073994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
    Harenberg J; Wehling M
    Semin Thromb Hemost; 2008 Feb; 34(1):39-57. PubMed ID: 18393142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
    Baglin T
    Br J Haematol; 2013 Oct; 163(2):160-7. PubMed ID: 23937286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New oral anticoagulants: prospects].
    Fiessinger JN
    Rev Prat; 2010 May; 60(5):613-6. PubMed ID: 20564841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
    Ufer M
    Thromb Haemost; 2010 Mar; 103(3):572-85. PubMed ID: 20135071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brave new world: the current and future use of novel anticoagulants.
    Spyropoulos AC
    Thromb Res; 2008; 123 Suppl 1():S29-35. PubMed ID: 18835010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will warfarin ever be replaced?
    Ruff CT; Braunwald E
    J Cardiovasc Pharmacol Ther; 2010 Sep; 15(3):210-9. PubMed ID: 20484119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?
    Rosencher N; Bellamy L; Arnaout L
    Arch Cardiovasc Dis; 2009 Apr; 102(4):327-33. PubMed ID: 19427610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New anticoagulants--are we prepared?].
    Pawlikowska Z; Szponar J
    Przegl Lek; 2012; 69(8):483-5. PubMed ID: 23243913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
    Sattari M; Lowenthal DT
    Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
    Schellong S
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
    Mousa SA
    Methods Mol Biol; 2010; 663():181-201. PubMed ID: 20617418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.